Compare AbCellera Biologics Inc (ABCL) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? AbCellera Biologics Inc trades at $9.98 (market cap $2.99B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.37 (market cap $15.33M). The key difference: AbCellera Biologics Inc is far larger — about 195× Avalanche Treasury Corporation Class A Common Stock's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| ABCL | AVAT | |
|---|---|---|
Market Cap | $2.99B | $15.33M |
Sector | Health | Financials |
52-Week High | $9.76 | $10.75 |
52-Week Low | $2.78 | $0.30 |
Enterprise Value | $2.58B | $15.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
AVAT trades at $0.37, up 9.83% in the past 24 hours. The stock shows a bearish technical signal with negative cash flow from operations of -$930,710 in 2025, though net income is positive at $8.28 million. Recent news highlights its Nasdaq listing as an operating company focused on capital allocation.
The outlook is cautious due to weak operational cash flow and bearish technical indicators. Investment appeal hinges on improved profitability and cash generation. Key risks include execution challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
